Fueling global pharma pipelines: The rise of China’s innovations

.table-7913 td { padding: 1rem; } .table-7913-2 td { padding: 1rem; } .table-7913 tr:first-child td { white-space: wrap; } .table-7913 tr:not(:first-child) td:nth-child(5) { white-space: nowrap; } .table-7913 td p { vertical-align: top; text-align: left; }

China is increasingly contributing to biopharma innovations and driving transformative deals. Our experts share the latest trends and implications.

China has emerged as a pivotal hub for pharmaceutical R&D, drawing increasing interest from global pharma majors and investors alike. The share of Phase I-IV trials in China has steadily increased over the past decade, reaching 39 percent of the global total in 2023 (Exhibit 1). This trend reflects two critical factors:

1. The rising importance of the Chinese market to multinational pharmaceutical companies, with China included in more multi-regional clinical trials for their pipeline assets.
2. The growing…